Context Therapeutics Inc.

09/23/2024 | Press release | Distributed by Public on 09/23/2024 06:43

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.